Agennix AG to Present at Three Conferences in February

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - January 30, 2012) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced that the Company will be presenting at three conferences in February.

Close Brothers Seydler Bank AG Small and Mid Cap Conference, Frankfurt
Agennix will give a presentation at the Close Brothers Seydler Bank AG Small and Mid Cap Conference. The presentation will be on Wednesday, February 1, 2012, at 12:30 CET at the IHK Frankfurt (Boerse), Frankfurt am Main, Germany.

German Science Day, Berlin
The Company will give a presentation and participate in a panel discussion on cancer immunotherapies and oligonucleotides as part of German Science Day at the University hospital Charité in Berlin, Germany. The presentation is scheduled for Thursday, February 2, 2012, at 15:35 CET. A live webcast of the presentation in German will be available through the Agennix Web site at www.agennix.com. A replay in German and English will be available on the Web site following the live event.

The First German Science Day - Fight Cancer, an initiative of the German biotechnology industry, will take place on the occasion of World Cancer Day. The event will highlight the major research and development contributions of German biotechnology companies working in the field of cancer to the press, investors and analysts. More information on German Science Day (German language only) can be found at www.german-science-day.com.

BIO CEO & Investor Conference, New York City
Agennix will also give a presentation at the 14th Annual BIO CEO & Investor Conference in New York, NY, USA. The presentation is scheduled for Tuesday, February 14, 2012 at 11:00 AM ET/17:00 CET at the Waldorf Astoria Hotel. A live audio webcast will be available through the Agennix Web site at www.agennix.com. A replay will be available on the Web site following the live event.

About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company’s most advanced program is talactoferrin, an oral immunotherapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer and in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer and in a Phase II/III trial in severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing for cancer, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix’s registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. The achievement of positive results in early stage clinical studies does not ensure that later stage or large scale clinical studies will be successful. Even if the results from our later stage trials with talactoferrin, including the ongoing FORTIS-M trial in non-small cell lung cancer, are considered positive, there can be no guarantee that they will be sufficient to gain marketing approval in the United States or any other country, and regulatory authorities may require additional information, data and/or further pre-clinical or clinical studies to support approval. In such event, there can be no guarantee that the Company will have or be able to obtain the financial resources to conduct any such additional studies or that such studies will yield results sufficient for approval. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.